These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33030229)

  • 1. Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During Chemoradiotherapy.
    Endo K; Ueno T; Hirai N; Komori T; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
    Laryngoscope; 2021 May; 131(5):E1524-E1529. PubMed ID: 33030229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy.
    Suzuki S; Yokota T; Notsu A; Hamauchi S; Onozawa Y; Fushiki K; Oshima K; Kawakami T; Tsushima T; Yasui H; Ogawa H; Onoe T; Kawatani K; Yamazaki K
    Oncologist; 2024 Oct; 29(10):e1315-e1323. PubMed ID: 38979778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma.
    Nishikawa D; Hanai N; Suzuki H; Koide Y; Beppu S; Hasegawa Y
    ORL J Otorhinolaryngol Relat Spec; 2018; 80(1):1-9. PubMed ID: 29393251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin.
    Weykamp F; Seidensaal K; Rieken S; Green K; Mende S; Zaoui K; Freier K; Adeberg S; Debus J; Welte SE
    Strahlenther Onkol; 2020 Jun; 196(6):515-521. PubMed ID: 31784802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia and Systemic Inflammation Synergistically Impact Survival in Oral Cavity Cancer.
    Lee J; Liu SH; Dai KY; Huang YM; Li CJ; Chen JC; Leu YS; Liu CJ; Chen YJ
    Laryngoscope; 2021 May; 131(5):E1530-E1538. PubMed ID: 33135827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
    Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
    BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Third Cervical Vertebra Skeletal Muscle Index in Oral Cavity Cancer: A Retrospective Study.
    Chang SW; Hsu CM; Tsai YH; Chang GH; Tsai MS; Huang EI; Tsai YT
    Laryngoscope; 2021 Jul; 131(7):E2257-E2265. PubMed ID: 33433021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.
    Okano S; Enokida T; Onoe T; Ota Y; Motegi A; Zenda S; Akimoto T; Tahara M
    Int J Clin Oncol; 2019 Jul; 24(7):789-797. PubMed ID: 30796560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer.
    Shirasu H; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Onitsuka T; Yurikusa T; Mori K; Yasui H
    BMC Cancer; 2020 Mar; 20(1):182. PubMed ID: 32131771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
    Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
    Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of sarcopenia on survival and treatment tolerance in patients with head and neck cancer treated with chemoradiotherapy.
    Bentahila R; Giraud P; Decazes P; Kreps S; Nay P; Chatain A; Fabiano E; Durdux C
    Cancer Med; 2023 Feb; 12(4):4170-4183. PubMed ID: 36263581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
    Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy.
    Aichi M; Hasegawa S; Kurita Y; Shinoda S; Kato S; Mizushima T; Yokota NR; Miyagi E
    Nutrition; 2023 May; 109():111966. PubMed ID: 36731243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bio-radiotherapy for locally advanced head and neck cancer: a monocentric case control study.
    Kawai S; Yokota T; Onozawa Y; Hamauchi S; Fukutomi A; Ogawa H; Onoe T; Onitsuka T; Yurikusa T; Todaka A; Tsushima T; Yoshida Y; Kito Y; Mori K; Yasui H
    BMC Cancer; 2017 Jan; 17(1):59. PubMed ID: 28095814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
    Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
    Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia with inflammation as a predictor of survival in patients with head and neck cancer.
    Yamahara K; Mizukoshi A; Lee K; Ikegami S
    Auris Nasus Larynx; 2021 Oct; 48(5):1013-1022. PubMed ID: 33883097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy.
    Mollnar S; Pondorfer P; Kasparek AK; Reinisch S; Moik F; Stotz M; Halm M; Szkandera J; Terbuch A; Eisner F; Gerger A; Kapp KS; Partl R; Vasicek S; Weiland T; Pichler M; Stöger H; Thurnher D; Posch F
    Clin Transl Oncol; 2021 Mar; 23(3):543-553. PubMed ID: 32671728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin.
    Bril SI; Al-Mamgani A; Chargi N; Remeijer P; Devriese LA; de Boer JP; de Bree R
    Head Neck; 2022 Jan; 44(1):189-200. PubMed ID: 34713519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.